XML 83 R67.htm IDEA: XBRL DOCUMENT v3.5.0.1
Equity Instruments (Details Textual)
9 Months Ended 12 Months Ended
Mar. 31, 2016
USD ($)
$ / shares
shares
Mar. 31, 2015
USD ($)
Jun. 30, 2015
USD ($)
Stock / Plan
shares
Jun. 30, 2014
USD ($)
shares
Jun. 02, 2015
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number Of Stock Option Plans | Stock / Plan     2    
Common Stock, Capital Shares Reserved for Future Issuance | shares 1,718,828,000,000   1,718,828,000,000    
Allocated Share-based Compensation Expense     $ 1,018,000 $ 500,000  
Conversion of Stock, Description The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents pursuant to the private placement memorandum. The exercise price will be the conversion price per share at which the first outstanding Note converts into Company common stock. The warrants have a term of five years from August 31, 2015 due to the conversion setting the price of these warrants (see Note 8).        
Fair Value Assumptions, Expected Term 5 years        
Share Based Compensation Share Warrants Issued on Convertible Promisory Notes | shares 267,052        
Share Based Compensation Share Warrants Issued on Convertible Promisory Notes, Weighted Average Exercise Price | $ / shares $ 0.65        
Adjustment To Additional Capital Issuance Of Warrants Related To Convertible Promissory Note $ 87,000 $ 0      
Issuance of Stock and Warrants for Services or Claims     $ 313,000    
Luoxis Diagnostics [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common Stock, Capital Shares Reserved for Future Issuance | shares     1,102,761    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares 3,717,500   195,189 33,083  
Vyrix Pharmaceuticals Inc [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common Stock, Capital Shares Reserved for Future Issuance | shares     616,067    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares     0 117,053  
Ampio Board And Employees [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures, Total $ 1,447,500        
Ampio [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Allocated Share-based Compensation Expense 1,300,000        
2013 Stock Option Plan [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Allocated Share-based Compensation Expense     $ 27,000    
Luoxis 2013 [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total     422,000    
Reversal Of Allocated Share Based Compensation Expense $ 433,000   433,000    
2015 Stock Option and Incentive Plan [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance | shares         10,000,000
Vyrix 2013 [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total     $ 189,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares     0